	US 11,919,964 B2
	Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
Gunasekaran Kannan, Daly City, CA (US); Ling Liu, Thousand Oaks, CA (US); Edward J. Belouski, Thousand Oaks, CA (US); and Cen Xu, Newbury Park, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Aug. 27, 2020, as Appl. No. 17/005,202.
Application 17/005,202 is a continuation of application No. 15/511,176, granted, now 10,934,362, previously published as PCT/US2015/050115, filed on Sep. 15, 2015.
Claims priority of provisional application 62/050,737, filed on Sep. 15, 2014.
Prior Publication US 2021/0047422 A1, Feb. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/18 (2006.01)

CPC C07K 16/2869 (2013.01) [C07K 16/18 (2013.01); C07K 16/28 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

33 Claims

1. A bispecific heterodimeric antibody comprising a first light chain (LC1) and a first heavy chain (HC1) from a first antibody that specifically binds to human CGRP receptor and a second light chain (LC2) and second heavy chain (HC2) from a second antibody that specifically binds to the amino-terminal extracellular domain of human PAC1 receptor, wherein LC2 comprises a light chain variable region (VL2) comprising a CDRL1, CDRL2, and CDRL3 and HC2 comprises a heavy chain variable region (VH2) comprising a CDRH1, CDRH2, and CDRH3, and wherein:

(a) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 1, 14 and 20, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 55, 66 and 74, respectively;

(b) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 2, 15 and 21, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 56, 67 and 75, respectively;

(c) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 3, 15 and 21, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 56, 67 and 75, respectively; or

(d) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 4, 16 and 22, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 57, 68 and 76, respectively.